<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306579</url>
  </required_header>
  <id_info>
    <org_study_id>054B26A43722225</org_study_id>
    <nct_id>NCT00306579</nct_id>
  </id_info>
  <brief_title>Myocardial Damage In Patients With Cerebral Infarction</brief_title>
  <official_title>Myocardial Damage In Patients With Cerebral Infarction. Prevalence and Characteristics as Measured by Troponins, Electrocardiographic Changes and Myocardial Perfusion Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonden for Lægevidenskabelig Forskning for Fyns Amt.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AJ Andersen og Hustrus Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Overlægerådet Legatudvalg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Raimond and Dagmar Ringgård-Bohn's Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bankdirektør Hans Stener og hustru Agnes Steners legat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Heart Foundation</source>
  <brief_summary>
    <textblock>
      Introduction&#xD;
&#xD;
      For several years &quot;ischemic&quot; electrocardiographic (ECG) changes in the acute phase of&#xD;
      ischemic stroke have been reported. Whether these ECG changes reflect true myocardial&#xD;
      ischemia remains controversial. So far no study has assessed different markers of myocardial&#xD;
      ischemia or necrosis in consecutive patients admitted to hospital with an acute ischemic&#xD;
      stroke.&#xD;
&#xD;
      Purpose&#xD;
&#xD;
      The main purpose of this study is to determine the potential burden of reversible and&#xD;
      irreversible myocardial ischemia in patients with an acute ischemic stroke.&#xD;
&#xD;
      Patients and methods&#xD;
&#xD;
      Serial blood samples for measuring troponin T, CK-MB and NT-proBNP are collected in 250&#xD;
      patients with evidence of an acute ischemic stroke admitted to the Department of Neurology at&#xD;
      Odense University Hospital. In addition resting 12-lead ECG recordings will be obtained on a&#xD;
      daily basis, and a 24-hour ST-segment ambulatory monitoring will be performed once within the&#xD;
      first week of hospitalisation. Finally, myocardial perfusion patterns during rest will be&#xD;
      evaluated by means of a myocardial perfusion scintigraphy in patients with an elevated&#xD;
      troponin T level.&#xD;
&#xD;
      Six months later control measurements of troponin T, CK-MB and NT-proBNP and a 12-lead ECG&#xD;
      will be obtained.&#xD;
&#xD;
      Expectations&#xD;
&#xD;
      The study will contribute with original observations in patients with acute ischemic stroke&#xD;
      considering the following issues:&#xD;
&#xD;
        1. The prevalence and characteristics of ECG changes suggestive of myocardial ischemia.&#xD;
&#xD;
        2. The prevalence of transient ST-segment changes on ambulatory monitoring.&#xD;
&#xD;
        3. The prevalence and degree of myocardial necrosis as judged from biochemical markers.&#xD;
&#xD;
        4. The prevalence of reversible and irreversible perfusion defects on myocardial&#xD;
           scintigraphy.&#xD;
&#xD;
        5. The prevalence, size and patterns of NT-proBNP.&#xD;
&#xD;
        6. Whether there is a change in ECG and biochemical markers over a 6-month follow-up&#xD;
           period.&#xD;
&#xD;
      The results may have clinical implications regarding early and late treatment as well as&#xD;
      clinical follow-up of patients recovering from an episode of acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date>May 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>250</enrollment>
  <condition>Ischemic Stroke</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke.&#xD;
&#xD;
          2. Age ≥ 18 years old.&#xD;
&#xD;
          3. Written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Onset of stroke symptoms 8 to 21 days before admission.&#xD;
&#xD;
          2. Transient ischemic attack.&#xD;
&#xD;
          3. Intracerebral or subarachnoid haemorrhage.&#xD;
&#xD;
          4. Previous myocardial infarction.&#xD;
&#xD;
          5. Any pathological Q waves on the baseline ECG.&#xD;
&#xD;
          6. Current atrial fibrillation.&#xD;
&#xD;
          7. Unstable angina pectoris ≤ 3 weeks before admission.&#xD;
&#xD;
          8. Systolic blood pressure ≤ 90 mmHg and symptoms.&#xD;
&#xD;
          9. Resuscitation after cardiac arrest.&#xD;
&#xD;
         10. Unwillingness to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper K. Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Mickley, DMSci</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Bak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Neurology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poul Flemming H. Carlsen, DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nuclear Medicine, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren R. Kristensen, DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Clinical Chemistry, Aalborg Hospital</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Myocardial necrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

